# A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers

> **NCT04879849** · PHASE1 · COMPLETED · sponsor: **Takeda** · enrollment: 34 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Triple Negative Breast Neoplasms
- Squamous Cell Carcinoma of Head and Neck

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** TAK-676
- **RADIATION:** Image-guided radiation therapy

## Key facts

- **NCT ID:** NCT04879849
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-09
- **Primary completion:** 2024-04-30
- **Final completion:** 2024-04-30
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2025-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04879849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04879849, "A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04879849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*